In this presentation, Misty Good, MD, MS, discusses new developments in the prevention and management of NEC, with a focus on IL-22 signaling as a target. Dr. Good reviews established and novel research techniques used to assess NEC, including mouse models and intestine-on-a-chip methods, and the ways in which these tools have helped further basic and translational NEC research. This presentation highlights the importance of preclinical research in the development of novel therapeutics, which is encapsulated by the studies that identified the potential role of IL-22 in NEC pathology and generated candidate therapeutics for future evaluation in the clinic.